astaxanthine has been researched along with Hemolysis* in 2 studies
2 other study(ies) available for astaxanthine and Hemolysis
Article | Year |
---|---|
Amyloid β-induced erythrocytic damage and its attenuation by carotenoids.
The presence of amyloid β-peptide (Aβ) in human blood has recently been established, and it has been hypothesized that Aβ readily contacts red blood cells (RBC) and oxidatively impairs RBC functions. In this study, we conducted in vitro and in vivo studies, which provide evidence that Aβ induces oxidative injury to RBC by binding to them, causing RBC phospholipid peroxidation and diminishing RBC endogenous carotenoids, especially xanthophylls. This type of damage is likely to injure the vasculature, potentially reducing oxygen delivery to the brain and facilitating Alzheimer's disease (AD). As a preventive strategy, because the Aβ-induced RBC damage could be attenuated by treatment of RBC with xanthophylls, we suggest that xanthophylls may contribute to the prevention of AD. Topics: Amyloid beta-Peptides; Animals; Antioxidants; Carotenoids; Erythrocytes; Flow Cytometry; Hemolysis; Humans; Lipid Peroxides; Lutein; Male; Mice; Mice, Inbred C57BL; Oxidation-Reduction; Oxidative Stress; Peptide Fragments; Phospholipids; Protein Binding; Xanthophylls | 2011 |
Disodium Disuccinate Astaxanthin (Cardax) attenuates complement activation and reduces myocardial injury following ischemia/reperfusion.
Carotenoids are a naturally occurring group of compounds that possess antioxidant properties. Most natural carotenoids display poor aqueous solubility and tend to form aggregates in solution. Disodium disuccinate astaxanthin (DDA; Cardax) is a water-dispersible synthetic carotenoid that rapidly and preferentially associates with serum albumin, thereby preventing the formation of supramolecular complexes and facilitating its efficacy after parenteral administration. This study investigated the ability of DDA to reduce inflammation and myocardial injury in a rabbit model of ischemia/reperfusion. DDA (50 mg/kg/day) or saline was administered i.v. for 4 consecutive days before the initiation of the protocol for induction of myocardial ischemia/reperfusion. On the 5th day, rabbits underwent 30 min of coronary artery occlusion, followed by a 3-h reperfusion period. Myocardial infarct size, as a percentage of the area at risk, was calculated for both groups. Infarct size was 52.5 +/- 7.5% in the vehicle-treated (n = 9) and 25.8 +/- 4.7% in the DDA-treated (n = 9) animals (p < 0.01 versus vehicle; mean myocardial salvage = 51%). To evaluate the anti-inflammatory effects of DDA, complement activity was assessed at the end of reperfusion using a red blood cell lysis assay. DDA administration significantly reduced (p < 0.01) the activation of the complement system in the serum. The current results, coupled with the well established antioxidant ability of carotenoids, suggest that the mechanism(s) of action by which DDA reduces the tissue damage associated with reperfusion injury may include both antioxidant and anticomplement components. Topics: Adjuvants, Immunologic; Animals; beta Carotene; C-Reactive Protein; Complement Activation; Complement Inactivator Proteins; Complement Membrane Attack Complex; Erythrocytes; Fluorescent Antibody Technique; Hemodynamics; Hemolysis; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Rabbits; Tetrazolium Salts; Thiazoles; Tissue Distribution; Troponin I; Xanthophylls | 2005 |